Tue. Sep 29th, 2020

Fxtriangle | Market analysis | Managed trading

Fxtriangle will make Fx trading look easy.

Panacea Biotec surges 20% on collaboration with US firm for coronavirus vaccine

2 min read

Shares of Panacea Biotec surged 20% on Wednesday — hitting the upper circuit at ₹202.80 apiece on BSE — after the company announced collaboration with US firm Refana for development, manufacturing and distribution of coronavirus vaccine.

From the beginning of the year, Panacea shares gained 53.93% to ₹202.80 against a fall of 17.37% in the the benchmark index Sensex.  From the March lows the stock gained 125.33%, whereas Sensex gained 15.99%.

“Panacea Biotec under the collaboration, is advancing its response to address the unprecedented challenges of covid-19 with Refana Inc. USA to make covid-19 vaccine widely accessible around the world in an equitable manner through a joint venture company to be based in Ireland,” Panacea Biotec said in a statement to the exchange.


Rajesh Jain, Managing Director, Panacea Biotec, said, “The world needs a vaccine that is safe, effective, and scalable in a current good manufacturing practice (cGMP) compliant manufacturing facility that has sizeable capacity and capability to cater to global demand. Our collaboration with Refana aims to manufacture over 500 million doses of our covid-19 candidate vaccine, with over 40 million doses expected to be available for delivery early next year”.

The collaboration aims to bring to patients a whole inactivated virus-based vaccine for covid-19. Under the collaboration, Panacea Biotec will be responsible for product development and commercial manufacturing, with the joint venture company undertaking clinical development and regulatory submissions across the World. Both Panacea and Refana will undertake sales and distribution of the vaccine in their respective territories, it said in its release.


Leave a Reply

Forex trading and any instruments related to Foreign Exchange Market are Speculative and carry substantial risk of loss of either partial equity or the entire deposit amount. Leverage adds up to the risk, before considering to invest in this venture, you should first consider your financial position and may seek the help of an independent financial advisor. FXtriangle dis-recommends the usage of loan instruments to trade in this market as it can hamper financial position. Please do not invest the money that you cannot afford to lose. FXtriangle provides all its services throughout the Globe Excluding (Nigeria, British Virgin Island & the Islamic Republic of Iran) and also provides limited service in some jurisdictions where investment in Overseas markets / Fx Exchanges are prohibited by Law If you are not sure to contact us before using any of our services. FXtriangle acts as an Independent Corporate Financial Advisor and connects you to various overseas exchanges and cannot be held liable for any financial damage occurring through their side. All of our partnered institutions are regulated in various jurisdictions.FXtriangle conducts an independent background check before partnering with any institutions to fulfill your investment objectives smoothly. The usage of our Business name, Logo or any trademark in any financial forum, website, review website, complaint arena, Billboards without our written permission will attract lawsuits.